Filter by patients with: All

What is ALS Phase 3 Study TRO19622?

Category: Others

false

See also: Clinical Trial

NCT01285583 is an open-label safety extension study of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole. The drug TRO19622 is also known as olesoxime. Other study names are TRO19622 CL E Q 1425-1.

See patients taking ALS Phase 3 Study TRO19622

Reported purpose & perceived effectiveness
Purpose Patients Evaluations Perceived Effectiveness
Participate in clinical trial 3 3
  • Major
  • Moderate
  • Slight
  • None
  • Can't tell
See all 5 patients that have used ALS Phase 3 Study TRO19622

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 0
Moderate 0
Mild 0
None 4

Commonly reported side effects and conditions associated with ALS Phase 3 Study TRO19622

Side effect Patients Percentage

Why patients stopped taking ALS Phase 3 Study TRO19622

Multiple reasons could be selected

Reason Patients Percentage
Did not seem to work 1
Other 1
See all 2 patients who've stopped using ALS Phase 3 Study TRO19622

Duration

Stopped using ALS Phase 3 Study TRO19622

Duration Patients Percentage
1 - 2 years 1
2 - 5 years 1
Adherence
Adherence Evaluations Percentage
Always 4
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations Percentage
Very hard to take 0
Somewhat hard to take 0
A little hard to take 1
Not at all hard to take 3
Cost per month
Cost per month Evaluations Percentage
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 1
Not specified 3
Last updated:

2 patient evaluations for ALS Phase 3 Study TRO19622

Sort by: Most recent

Dec 28, 2011 (Started Nov 17, 2009)

  • Effectiveness
    None (for Participate in clinical trial)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    A little hard to take
Dosage: 1 mg Daily
Cost: < $25 monthly
  • 0 helpful marks

Dec 14, 2011 (Started Feb 25, 2010)

  • Effectiveness
    None (for Participate in clinical trial)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    Not at all hard to take
Dosage: 2 other Daily
Advice & Tips: Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Phasellus faucibus turpis sed mi maximus mattis.

Sep 1, 2011 (Started Feb 25, 2010)

  • Effectiveness
    Can't tell (for may slow ALS)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    Not at all hard to take
Dosage: 2 other Daily
Advice & Tips: Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Phasellus faucibus turpis sed mi maximus mattis.
  • 0 helpful marks
Last updated:
Showing 2 of 2 patient evaluations for ALS Phase 3 Study TRO19622